Women’s health company Sera Prognostics has secured a $19.3 million series A financing led by venture capital firms InterWest Partners, Domain Associates and Catalyst Health Ventures. The company’s founder UpStart Life Sciences Capital and new investor Osage University Partners also participated in the funding round.
The proceeds will be used to complete the firm’s multi-center Proteomic Assessment of Preterm Risk (PAPR) clinical trial of its preterm birth diagnostic and commercially introduce the test with the aim of demonstrating clinical advantage and economic savings under real-world conditions. Additionally, Sera has hired Gregory Critchfield, current chairman of its board of directors, as CEO.
Click here for the release from Sera Prognostics.